No

Antifungal Agent, Vaginal

Treatment of vulvovaginitis caused by Candida albicans

C (avoid use after 7th month)

Hypersensitivity to sulfanilamide or any component

Since sulfonamides may be absorbed from vaginal mucosa, the same precaution for oral sulfonamides apply (eg, blood dyscrasias); if a rash develops, terminate therapy immediately. Use vaginal applicators very cautiously after the 7th month of pregnancy.

Percentage unknown: Rarely, systemic reactions occur; increased discomfort, burning, allergic reactions, Stevens-Johnson syndrome (infrequent)

Worsens the toxic effects of oral hypoglycemia, oral anticoagulants, phenytoin

Interferes with microbial folic acid synthesis and growth via inhibition of para-aminiobenzoic acid metabolism; exerts a bacteriostatic action

Adults: Female: Insert one applicatorful intravaginally once or twice daily continued through 1 complete menstrual cycle or insert one suppository intravaginally once or twice daily for 30 days

None reported

None reported

No information available to require special precautions

No effects or complications reported

Complete full course of therapy as directed. Insert vaginally as directed by prescriber or see package insert. You may be sensitive to direct sunlight (wear protective clothing, use sunblock, and avoid excessive exposure to direct sunlight). Sexual partner may experience irritation of penis; best to refrain from intercourse during period of treatment. Report persistent vaginal burning, itching, or irritation; rash; yellowing of eyes or skin, dark urine, or pale stool; unresolved nausea or vomiting; or painful urination. Breast-feeding precautions: Do not breast-feed.

Avoid excessive exposure to sunlight; complete full course of therapy; notify physician if burning or irritation become severe or persist or if allergic symptoms occur

Cream, vaginal (AVC™, Vagitrol®): 15% [150 mg/g] (120 g with applicator)

Suppository, vaginal (AVC™): 1.05 g (16s)